Preview

Южно-Российский журнал терапевтической практики

Расширенный поиск

Резистентная гипертония: фокус на поражение сосудистого русла

https://doi.org/10.21886/2712-8156-2020-1-3-16-26

Полный текст:

Аннотация

Понятие резистентной артериальной гипертензии было введено много лет назад и подтверждено в обновленном научном заявлении Американской кардиологической ассоциации (АНА) 2018 и последних рекомендациях Европейского обществ кардиологов (ESC) 2018. Особое внимание к данной группе больных обусловлено высоким риском неблагоприятных исходов по сравнению с контролируемой гипертонией. В настоящем обзоре мы хотим не просто осветить трудности выявления, оценки и оптимизации терапии больных с резистентной АГ, но в большей степени сосредоточиться на основных механизмах формирования истинной резистентности, их выявлении и поиске оптимального пути воздействия.

Об авторах

М. С. Литвинова
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России; МБУЗ Клинико-диагностический центр «Здоровье»
Россия

Литвинова Марина Сергеевна, аспирант кафедры терапии

Ростов-на-Дону



Л. А. Хаишева
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
Россия

Хаишева Лариса Анатольевна, д.м.н., профессор кафедры терапии

Ростов-на-Дону



С. В. Шлык
ВО «Ростовский государственный медицинский университет» Минздрава России
Россия

Шлык Сергей Владимирович, д.м.н., профессор, ректор

Ростов-на-Дону 



Список литературы

1. Gifford RW Jr, Tarazi RC. Resistant hypertension: diagnosis and management. Ann Intern Med. 1978;88(5):661-5. doi: 10.7326/0003-4819-88-5-661

2. Резник Е.В., Никитин И.Г. Новые рекомендации АСС/ AHA и ESC/ESH по артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2018;17(5):99-119. doi: 10.15829/1728-8800-2018-5-99-119

3. Рабочая группа по лечению артериальной гипертензии Европейского общества кардиологов (ЕОК, ESC) и Европейского общества по артериальной гипертензии (ЕОАГ, ESH). 2018 ЕОК/ЕОАГ Рекомендации по лечению больных с артериальной гипертензией. Российский кардиологический журнал. 2018;(12):143-228. doi: 10.15829/1560-4071-2018-12-143-228

4. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016;10:493–499. doi: 10.1016/j.jash.2016.03.186

5. Messerli FH, Ventura HO, Amodeo C. Osler’s maneuver and pseudohypertension. N Engl J Med. 1985;312:1548–1551. doi: 10.1056/NEJM198506133122405

6. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P. at al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902. doi: 10.1161/HYPERTENSIONAHA.110.168948

7. Nasothimiou EG, Tzamouranis D, Roussias LG, Stergiou GS. Home versus ambulatory blood pressure monitoring in the diagnosis of clinic resistant and true resistant hypertension. J Hum Hypertens. 2012;26(12):696-700. doi: 10.1038/jhh.2011.98.

8. Manios ED, Koroboki EA, Tsivgoulis GK, Spengos KM, Spiliopoulou IK, Brodie FG, eet al. Factors influencing whitecoat effect. Am J Hypertens. 2008;21(2):153-8. doi: 10.1038/ajh.2007.43

9. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–2346. doi: 10.1001/archinte.168.21.2340

10. Franklin SS, Thijs L, Asayama K, Li Y, Hansen TW, Boggia J, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033–2043. doi: 10.1016/j.jacc.2016.08.035

11. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691–697. doi: 10.1161/HYPERTENSIONAHA.113.01448

12. Hameed MA, Tebbit L, Jacques N, Thomas M, Dasgupta I. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30:83–89. doi: 10.1038/jhh.2015.38

13. Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–676. doi: 10.1016/j.ijcard.2016.06.263

14. Van der Laan DM, Elders PJM, Boons CCLM, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication nonadherence: a systematic review. J Hum Hypertens. 2017;31:687–694. doi: 10.1038/jhh.2017.48

15. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54. doi: 10.1111/j.1751-7176.2008.07572.x

16. Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29:213–218. doi: 10.1038/jhh.2014.

17. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4

18. Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR Medication Adherence and Persistence Special Interest Group. Value Health. 2013;16:863–871. doi: 10.1016/j.jval.2013.03.1631

19. Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am. 2017;101:229–245. doi: 10.1016/j.mcna.2016.08.005

20. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898–909. doi: 10.1111/j.1751-7176.2011.00550

21. Fowler FJ Jr, Gerstein BS, Barry MJ. How patient centered are medical decisions? Results of a national survey. JAMA Intern Med. 2013;173:1215–1221. doi: 10.1001/jamainternmed.2013.6172

22. Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535. doi: 10.1007/s11906-015-0535-3

23. Nakanishi M, Mizuno T, Mizokami F, Koseki T, Takahashi K, Tsuboi N, et al. Impact of pharmacist intervention for blood pressure control in patients with chronic kidney disease: A meta-analysis of randomized clinical trials [published online ahead of print, 2020 Sep 19]. J Clin Pharm Ther. 2020;10.1111/jcpt.13262. doi: 10.1111/jcpt.13262

24. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012 Apr 3;125(13):1635-42. doi: 10.1161/CIRCULATIONAHA.111.068064

25. Petersen J, Malyutina S, Ryabikov A, Kontsevaya A, Kudryavtsev AV, Eggen AE, et al. Uncontrolled and apparent treatment resistant hypertension: a cross-sectional study of Russian and Norwegian 40-69 year olds. BMC Cardiovasc Disord. 2020;20(1):135. doi: 10.1186/s12872-020-01407-2

26. Achelrod D, Wenzel U, Frey S. Systematic review and metaanalysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28:355–61. doi: 10.1093/ajh/hpu151.

27. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404. doi: 10.1111/j.1524-6175.2002.02045.x

28. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-43. doi: 10.1097/HJH.0000000000000051

29. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-54. doi: 10.1093/eurheartj/eht534

30. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167(22):2431-6. doi: 10.1001/archinte.167.22.2431

31. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-58. doi: 10.1161/CIRCULATIONAHA.111.030189

32. Acharya T, Tringali S, Singh M, Huang J. Resistant hypertension and associated comorbidities in a veterans affairs population. J Clin Hypertens (Greenwich). 2014;16(10):741-5. doi: 10.1111/jch.12410

33. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622-32. doi: 10.1038/ki.2015.142

34. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686-95. doi: 10.1093/eurheartj/ehv392.

35. Egan BM, Kai B, Wagner CS, Henderson JH, Chandler AH, Sinopoli A. Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Hypertens (Greenwich). 2016;18(8):817-24. doi: 10.1111/ jch.12773.

36. Carris NW, Ghushchyan V, Libby AM, Smith SM. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. J Hum Hypertens. 2016;30(3):191-6. doi: 10.1038/jhh.2015.61.

37. Концевая А.В., Романенко Т.С., Худяков М.Б. Ресурсное обеспечение лечения артериальной гипертензии в реальной клинической практике амбулаторно-поликлинических учреждений. Артериальная гипертензия. 2017;23(1):25-35. Doi: 10.18705/1607-419X-2017-23-1-25-35

38. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105. doi: 10.1136/heartjnl-2018-313599

39. Georgianos PI, Agarwal R. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda. Curr Hypertens Rep. 2020;22(10):84. doi: 10.1007/s11906-020-01081-x.

40. Herrmann SM, Textor SC. Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens. 2018;31(2):139-149. doi: 10.1093/ajh/hpx154

41. Benjamin MM, Fazel P, Filardo G, Choi JW, Stoler RC. Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension. Am J Cardiol. 2014;113(4):687-90. doi: 10.1016/j.amjcard.2013.10.046

42. Patel SM, Li J, Parikh SA. Renal Artery Stenosis: Optimal Therapy and Indications for Revascularization. Curr Cardiol Rep. 2015;17(9):623. doi: 10.1007/s11886-015-0623-7

43. Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Balk EM. Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review. Ann Intern Med. 2016;165(9):635-649. doi: 10.7326/M16-1053

44. Kline GA, Prebtani APH, Leung AA, Schiffrin EL. Primary aldosteronism: a common cause of resistant hypertension.CMAJ. 2017;189(22):E773-E778. doi: 10.1503/cmaj.161486.

45. Молашенко Н.В., Трошина Е.А. Первичный идиопатический гиперальдостеронизм в клинической практике. Ожирение и метаболизм. 2012;4(33):3-9. eLIBRARY ID: 18839494

46. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. doi: 10.1210/jc.2015-4061

47. Grasso M, Boscaro M, Scaroni C, Ceccato F. Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High Blood Press Cardiovasc Prev. 2018;25(4):345-354. doi: 10.1007/s40292-018-0288-6.

48. Corsello SM, Paragliola RM. Evaluation and Management of Endocrine Hypertension During Pregnancy. Endocrinol Metab Clin North Am. 2019;48(4):829-842. doi: 10.1016/j.ecl.2019.08.011.

49. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: 10.1530/EJE-16-0467

50. 50. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-31. doi: 10.1210/jc.2015- 1818.

51. Волкова Н.И., Давиденко И.Ю. Роль врача-терапевта в диагностике эндокринных артериальных гипертензий. Кардиоваскулярная терапия и профилактика. 2019;18(2):84-93. doi: 10.15829/1728-8800-2019-2-84-93

52. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens. 2012;30(6):1211-6. doi: 10.1097/HJH.0b013e328353634e.

53. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099-107. doi: 10.1016/j.mayocp.2013.06.017.

54. Kolwelter J, Uder M, Schmieder RE. Tissue sodium content in hypertension and related organ damage. J Hypertens. 2020. doi: 10.1097/HJH.0000000000002580. Epub ahead of print.

55. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P, Klisiewicz A et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013;27(11):678-85. doi: 10.1038/jhh.2013.32.

56. Gottlieb DJ, Punjabi NM. Diagnosis and Management of Obstructive Sleep Apnea: A Review. JAMA. 2020;323(14):1389-1400. doi: 10.1001/jama.2020.3514

57. Itani O, Jike M, Watanabe N, Kaneita Y. Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med. 2017;32:246-256. doi: 10.1016/j.sleep.2016.08.006.

58. Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60:653–658. doi: 10.1161/HYPERTENSIONAHA.112.197780

59. Guimarães GV, Cruz LG, Tavares AC, Dorea EL, Fernandes-Silva MM, Bocchi EA. Effects of short-term heated water-based exercise training on systemic blood pressure in patients with resistant hypertension: a pilot study. Blood Press Monit. 2013;18(6):342-5. doi: 10.1097/MBP.0000000000000000.

60. Jurca SJ, Elliott WJ. Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects. Curr Hypertens Rep. 2016;18(10):73. doi: 10.1007/s11906-016-0682-1.

61. Pathan MK, Cohen DL. Resistant Hypertension: Where are We Now and Where Do We Go from Here? Integr Blood Press Control. 2020;13:83-93. doi: 10.2147/IBPC.S223334.

62. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.0000000000000033.

63. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of allcause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236-41. doi: 10.1161/01.hyp.37.5.1236.

64. Chung CM, Cheng HW, Chang JJ, Lin YS, Hsiao JF, Chang ST, et al. Relationship between resistant hypertension and arterial stiffness assessed by brachial-ankle pulse wave velocity in the older patient. Clin Interv Aging. 2014;9:1495-502. doi: 10.2147/CIA.S68544.

65. Einarsen E, Gerdts E, Waje-Andreassen U, Naess H, Fromm A, Saeed S. Association of increased arterial stiffness with diastolic dysfunction in ischemic stroke patients: the Norwegian Stroke in the Young Study. J Hypertens. 2020;38(3):467-473. doi: 10.1097/HJH.0000000000002297

66. Vlachopoulos C, Terentes-Printzios D, Laurent S, Nilsson PM, Protogerou AD, Aznaouridis K et al. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT. JAMA Netw Open. 2019;2(10):e1912831. doi: 10.1001/jamanetworkopen.2019.12831.

67. Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y et al. Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease: An Individual Participant Data Meta-Analysis. Hypertension. 2017;69(6):1045-1052. doi: 10.1161/HYPERTENSIONAHA.117.09097.

68. Cardoso CRL, Salles GC, Salles GF. Prognostic Impact of Aortic Stiffness in Patients With Resistant Hypertension. Hypertension. 2019;73(3):728-735. doi: 10.1161/HYPERTENSIONAHA.118.12367.

69. Ato D, Sawayama T. Factors associated with high brachialankle pulse wave velocity in non-hypertensive and appropriately treated hypertensive patients with atherosclerotic risk factors. Vasc Health Risk Manag. 2017;13:383-392. doi: 10.2147/VHRM.S144923.

70. Triantafyllidi H, Trivilou P, Ikonomidis I, Kontsas K, Tzortzis S, Pavlidis G, et al. Is Arterial Hypertension Control Enough to Improve Aortic Stiffness in Untreated Patients With Hypertension? A 3-Year Follow-Up Study. Angiology. 2015;66(8):759-65. doi: 10.1177/0003319714552811.

71. Zheng M, Huo Y, Wang X, Xu X, Qin X, Tang G et al. A prospective study on pulse wave velocity (PWV) and response to anti-hypertensive treatments: PWV determines BP control. Int J Cardiol. 2015;178:226-31. doi: 10.1016/j.ijcard.2014.10.049.

72. Agabiti-Rosei E, Rizzoni D. Microvascular structure as a prognostically relevant endpoint. J Hypertens. 2017;35(5):914-921. doi: 10.1097/HJH.0000000000001259.

73. Хаишева Л.А., Шлык С.В., Гарина И.А., Разумовский И.В., Деврижбекова З.М., Бекетов П.А. Изучение особенностей микроциркуляторного русла у пациентов с артериальной гипертензией и поражением органов-мишеней. Кубанский научный медицинский вестник. 2014;(4):120-126. doi: 10.25207/1608-6228-2014-4-120-126

74. Федорович А.А. Функциональное состояние регуляторных механизмов микроциркуляторного кровотока в норме и при артериальной гипертензии по данным лазерной допплеровской флоуметрии. Регионарное кровообращение и микроциркуляция. 2010;9(1):49-60. doi: 10.24884/1682-6655-2010-9-1-49-60

75. Imhof K, Zahner L, Schmidt-Trucksäss A, Hanssen H. Association of body composition and blood pressure categories with retinal vessel diameters in primary school children. Hypertens Res. 2016;39(6):423-9. doi: 10.1038/hr.2015.159.

76. Smith W, Malan NT, Schutte AE, Schutte R, Mels CM, Vilser W, et al. Corrigendum: Retinal vessel caliber and its relationship with nocturnal blood pressure dipping status: the SABPA study. Hypertens Res. 2016;39(10):752. doi: 10.1038/hr.2016.102. Erratum for: Hypertens Res. 2016;39(10 ):730- 736.

77. Triantafyllou A, Anyfanti P, Pyrpasopoulou A, Triantafyllou G, Aslanidis S, Douma S. Capillary rarefaction as an index for the microvascular assessment of hypertensive patients. Curr Hypertens Rep. 2015;17(5):33. doi: 10.1007/s11906-015-0543-3.

78. Serné EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ, Stehouwer CD. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension. 2001;38(2):238-42. doi: 10.1161/01.hyp.38.2.238.

79. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol. 1989;256(1 Pt 2):H126-31. doi: 10.1152/ajpheart.1989.256.1.H126.

80. Hirst A, Marshall JM. Endothelium-dependent and cyclooxygenase-dependent cutaneous vasodilatation is blunted in young men with hypertensive parents. J Hypertens. 2018;36(11):2140-2147. doi: 10.1097/HJH.0000000000001794.

81. Ватутин Н. Т., Склянная Е.В. Дисфункция эндотелия сосудов как фактор риска развития артериальной гипертензии. Сибирский медицинский журнал. 2017;32(4):23-7. doi: 10.29001/2073-8552-2017-32-4- 23-27

82. Горшков А.Ю., Федорович А.А., Драпкина О.М. Дисфункция эндотелия при артериальной гипертензии: причина или следствие? Кардиоваскулярная терапия и профилактика. 2019;18(6):62-68. Doi: 10.15829/1728-8800-2019-6-62-68

83. Горшунова Н.К., Медведев Н.В. Сопряженность гипертензивной эндотелиальной дисфункции с выраженностью миокардиальных поражений и хронической сердечной недостаточности у больных старшего возраста. Артериальная гипертензия. 2017;23(2):112-121. doi: 10.18705/1607-419X-2017-23-2-112-121

84. Булаева Н.И., Голухова Е.З. Эндотелиальная дисфункция и оксидативный стресс: роль в развитии кардиоваскулярной патологии. Креативная кардиология. 2013;1:14-22. eLIBRARY ID: 20314398

85. Чазова И. Е., Шестакова М. В., Жернакова Ю. В., Мар- кова Т. Н., Мазурина Н. В., Ежов М. В., и др. Российское медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020;17(1):7-45. doi: 10.26442/2075082X.2020.1.200051

86. Jiang J, Zheng JP, Li Y, Gan Z, Jiang Y, Huang D, et al. Differential contribution of endothelium-derived relaxing factors to vascular reactivity in conduit and resistance arteries from normotensive and hypertensive rats. Clin Exp Hypertens. 2016;38(4):393-8. doi: 10.3109/10641963.2016.1148155.

87. Balduino Mendes AB, Giollo-Junior LT, de Andrade DO, Gregório ML, Yugar-Toledo JC, Vilela-Martin JF. How to Investigate the Vascular Changes in Resistant Hypertension. Curr Hypertens Rev. 2016;12(2):139-47. doi: 10.2174/1573402111666150812143349.

88. Zhang Y, Dong E. New insight into vascular homeostasis and injury-reconstruction. Sci China Life Sci. 2014;57(8):739-41. doi: 10.1007/s11427-014-4719-x.

89. Kutikhin AG, Sinitsky MY, Yuzhalin AE, Velikanova EA. Shear stress: An essential driver of endothelial progenitor cells. J Mol Cell Cardiol. 2018;118:46-69. doi: 10.1016/j.yjmcc.2018.03.007.

90. Wu H, Chen H, Hu PC. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin Lab. 2007;53(5-6):285-95. PMID: 17605403.

91. Sen S, McDonald SP, Coates PT, Bonder CS. Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond). 2011;120(7):263-83. doi: 10.1042/CS20100429.

92. Koutroumpi M, Dimopoulos S, Psarra K, Kyprianou T, Nanas S. Circulating endothelial and progenitor cells: Evidence from acute and long-term exercise effects. World J Cardiol. 2012;4(12):312-26. doi: 10.4330/wjc.v4.i12.312

93. Топузова М.П., Алексеева Т.М., Вавилова Т.В., Сироткина О.В., Клочева Е.Г. Циркулирующие эндотелиоциты и их предшественники как маркер дисфункции эндотелия у больных артериальной гипертензией, перенесших ишемический инсульт (обзор). Артериальная гипертензия. 2018;24(1):57-64. Doi: 10.18705/1607-419X-2018-24-1-57-64

94. Luo S, Xia W, Chen C, Robinson EA, Tao J. Endothelial progenitor cells and hypertension: current concepts and future implications. Clin Sci (Lond). 2016;130(22):2029-2042. doi: 10.1042/CS20160587.

95. Chen L, Ding ML, Wu F, He W, Li J, Zhang XY, et al. Impaired Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Hypertensive Patients With Primary Hyperaldosteronemia: Role of 5,6,7,8-Tetrahydrobiopterin Oxidation and Endothelial Nitric Oxide Synthase Uncoupling. Hypertension. 2016;67(2):430-9. doi: 10.1161/HYPERTENSIONAHA.115.06597.

96. Yu BB, Zhi H, Zhang XY, Liang JW, He J, Su C, et al. Mitochondrial dysfunction-mediated decline in angiogenic capacity of endothelial progenitor cells is associated with capillary rarefaction in patients with hypertension via downregulation of CXCR4/JAK2/SIRT5 signaling. EBioMedicine. 2019;42:64-75. doi: 10.1016/j.ebiom.2019.03.031.

97. de Cavanagh EMV, González SA, Inserra F, Forcada P, Castellaro C, Chiabaut-Svane J, et al. Blood pressure control is not enough to normalize endothelial repair by progenitor cells. Am J Physiol Heart Circ Physiol. 2020;319(4):H744-H752. doi: 10.1152/ajpheart.00333.2020

98. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600. doi: 10.1056/NEJMoa022287.

99. Budzyń M, Gryszczyńka B, Boruczkowski M, Kaczmarek M, Begier-Krasińska B, Osińska A, et al. The endothelial status reflected by circulating endothelial cells, circulating endothelial progenitor cells and soluble thrombomodulin in patients with mild and resistant hypertension. Vascul Pharmacol. 2019;113:77-85. doi: 10.1016/j.vph.2018.12.005.

100. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, et al. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One. 2013;8(3):e60357. doi: 10.1371/journal.pone.0060357.

101. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010;459(6):793-806. doi: 10.1007/s00424-009-0767-7.

102. Ozüyaman B, Ebner P, Niesler U, Ziemann J, Kleinbongard P, Jax T, et al. Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells. Thromb Haemost. 2005;94(4):770-2. doi: 10.1160/TH05-01-0038.

103. Yang JX, Pan YY, Wang XX, Qiu YG, Mao W. Endothelial progenitor cells in age-related vascular remodeling. Cell Transplant. 2018;27(5):786-795. doi: 10.1177/0963689718779345.

104. Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700(1-3):201-9. doi: 10.1016/j.ejphar.2012.11.059.

105. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension. 2010;56(5):879-84. doi: 10.1161/HYPERTENSIONAHA.110.158071.

106. Yu X, Yang Z, Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren Fail. 2010;32(4):475-9. doi: 10.3109/08860221003664280.

107. Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press. 2015;24(1):7-13. doi: 10.3109/08037051.2014. 940710.

108. Norlander AE, Madhur MS, Harrison DG. Correction: The immunology of hypertension. J Exp Med. 2018;215(2):719. doi: 10.1084/jem.2017177301022018c. Erratum for: J Exp Med. 2018;215(1):21-33.

109. Barbaro NR, Harrison DG. Markers or Makers: Inflammatory Cytokines in Treatment-Resistant Hypertension. Hypertension. 2019;73(4):767-769. doi: 10.1161/HYPERTENSIONAHA.119.12604.

110. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93(3):621-35. doi: 10.1016/j.mcna.2009.02.015.

111. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97(8):1916-23. doi: 10.1172/JCI118623.

112. Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(7):1565-72. doi: 10.1161/ATVBAHA.111.227629.

113. Peyster E, Chen J, Feldman HI, Go AS, Gupta J, Mitra N, et al. Inflammation and Arterial Stiffness in Chronic Kidney Disease: Findings From the CRIC Study. Am J Hypertens. 2017;30(4):400-408. doi: 10.1093/ajh/hpw164.

114. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53(2):258-61. doi: 10.3349/ymj.2012.53.2.258.

115. Chen C, Zhu XY, Li D, Lin Q, Zhou K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(34):e21694. doi: 10.1097/MD.0000000000021694.

116. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013;64:233-47.doi: 10.1146/annurev-med-042711-135929.

117. Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017;26(1):14-19. doi: 10.1097/MNH.0000000000000286.

118. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25(9):532-8. doi: 10.1038/jhh.2010.95.

119. de Faria AP, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013;36(12):1067-72. doi: 10.1038/hr.2013.92.

120. Sabbatini AR, Faria AP, Barbaro NR, Gordo WM, Modolo RG, Pinho C, et al. Deregulation of adipokines related to target organ damage on resistant hypertension. J Hum Hypertens. 2014;28(6):388-92. doi: 10.1038/jhh.2013.118.

121. Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc Health Risk Manag. 2017;13:403-411. doi: 10.2147/VHRM.S138599.

122. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the reninangiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47(11):1936-9. doi: 10.1007/s00125-004-1542-0.

123. Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, Inflammation, Immune System and Hypertension. Am J Hypertens. 2020:hpaa137. doi: 10.1093/ajh/hpaa137. Epub ahead of print.

124. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone- induced inflammation in the rat heart : role of oxidative stress. Am J Pathol. 2002;161(5):1773-81. doi: 10.1016/S0002-9440(10)64454-9.

125. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflam-mation. Arterioscler Thromb Vasc Biol. 2006;26(4):917-21. doi: 10.1161/01.ATV.0000204635.75748.0f.

126. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59(2):324- 30. doi: 10.1161/HYPERTENSIONAHA.111.181123.

127. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102(11):1359-67. doi: 10.1161/CIRCRESAHA.108.174235.

128. Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J. 2011;32(10):1275-86. doi: 10.1093/eurheartj/ehq254.

129. Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, et al. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab. 2011;96(10):3175-83.doi: 10.1210/jc.2011-1135.


Дополнительные файлы

Для цитирования:


Литвинова М.С., Хаишева Л.А., Шлык С.В. Резистентная гипертония: фокус на поражение сосудистого русла. Южно-Российский журнал терапевтической практики. 2020;1(3):16-26. https://doi.org/10.21886/2712-8156-2020-1-3-16-26

For citation:


Litvinova M.S., Khaisheva L.A., Shlyk S.V. Resistant hypertension: focus on vascular lesions. South Russian Journal of Therapeutic Practice. 2020;1(3):16-26. (In Russ.) https://doi.org/10.21886/2712-8156-2020-1-3-16-26

Просмотров: 167


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2712-8156 (Print)